The COVID Boom: CBER Receives More INDs in One Quarter Than The Previous 30 Combined

Bubble was short-lived, but still could create workload problems for the US FDA as it navigates the end of the coronavirus pandemic.

Hand grabbing rising line
CBER continued to see INDs for cell and gene therapies, in addition to COVID-19 countermeasures, in recent months. • Source: Alamy

The coronavirus pandemic attracted a historic tsunami of investigational work to the US Food and Drug Administration’s Center for Biologics Evaluation and Research, which may affect its operations even after the pandemic ends.

Interestingly, however, the dramatic spike in investigational new drug applications only lasted six months, then largely disappeared. The activity may...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America